Home / 2017 / August

Month: August 2017

New Cannabis Ventures and 420Investor CFA Alan Brockstein joins to talk about the emerging opportunities in the Cannabis space, and how investors need to watch out as the darker underbelly of capital markets are attracted to the rich valuations currently being experienced in certain issuers.

Flawed Bill C-45 Could Defeat Canadian Cannabis Legislation’s Good Intentions

Within the text of Bill C-45 The Cannabis Act are sown the seeds for the program’s potential failure. The Liberal Government has limited time to change course and avoid both a price war and a flood of constitutional challenges.

The legislation is built on what superficially could be interpreted as contradictory targeted outcomes, and faulty assumptions.

The summary of Bill C-45’s first reading states “The objectives of the Act are to prevent young persons from accessing cannabis, to protect public health and public safety by establishing strict product safety and product quality require- ments and to deter criminal activity by imposing serious criminal penalties for those operating outside the legal framework. The Act is also intended to reduce the burden on the criminal justice system in relation to cannabis.”

That legislation alone can “prevent young persons from accessing cannabis” is …

VIDEO: Aphria Inc. (TSE:APH) Leamington Cannabis Grow Operations

Transcript:

James West: I’m James West. Welcome to another edition of the Midas Letter’s Cannabis Video Series. Today, we travel to Leamington, Ontario: home of licensed producer Aphria Inc. (TSE:APH), one of the few 100 percent greenhouse growers in the public markets.

Vic Neufeld:   If you understand Mother Nature, and what really does a plant need, it’s a very tailored process. It’s way ahead of our competition. A good crop is two things: are you maximizing yield per plant or per square foot, and secondly, is the potency that you’re expecting to test for, you actually got. So you could have one without the other, and then, nah…I want both.

Cory Cacciavillani:  Yeah. So there’s obviously things that we have to tailor towards the cannabis plant, but the science behind growing plants, especially on a commercial scale like we’re doing …

Aphria Inc. Leamington Cannabis Grow Operations Copy

Transcript:

James West: I’m James West. Welcome to another edition of the Midas Letter’s Cannabis Video Series. Today, we travel to Leamington, Ontario: home of licensed producer Aphria, one of the few 100 percent greenhouse growers in the public markets.

Vic Neufeld:   If you understand Mother Nature, and what really does a plant need, it’s a very tailored process. It’s way ahead of our competition. A good crop is two things: are you maximizing yield per plant or per square foot, and secondly, is the potency that you’re expecting to test for, you actually got. So you could have one without the other, and then, nah…I want both.

Cory Cacciavillani:  Yeah. So there’s obviously things that we have to tailor towards the cannabis plant, but the science behind growing plants, especially on a commercial scale like we’re doing here, really …

Dow 22,000: The Delusion Continues

With self-congratulatory accolades flowing effusively from within America starting at the top with Donald Trump, it behooves the objective market participant to recall the reasons that have caused the Dow’s meteroic rise to 22,000 points since the financial crisis broke in the first place.

Talking heads ala Bloomberg and CNBC point to earnings and the incredible growth in market cap of companies like Apple, Google, and Amazon, but without recognizing that the financial performance has been purchased with a debt to be paid by the as yet unborn.

Pretending that you’re the architect of your good fortune is fine if it is accomplished honestly. But such is not the case with the Dow or any metric of the U.S. financial system.

Essentially, the United States has fabricated (they called it “quantitative easing”)  a capital base of $4.5 trillion with the …

Free Newsletter,
Priceless Content.

Get more of Midas Letter delivered right to your inbox.

Special Offer

Sign-up today and receive free and immediate access to three recently published special reports!

Free Newsletter,
Priceless Content.

Get more of Midas Letter delivered right to your inbox.

Special Offer

Sign-up today and receive free and immediate access to three recently published special reports!